Best Diversified Pharmaceuticals Companies in England, United Kingdom
The 36 best Diversified Pharmaceuticals companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AstraZeneca.
Ranked: Best Diversified Pharmaceuticals companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | AstraZeneca Developer of pharmaceutical medicines for oncology and various chronic diseases | $4.1B | 14 mo ago | 83,100 | Pascal Soirot CEO | 2,817 patents Therapeutic antibodies and antibody‑drug conjugates for oncology and SARS‑CoV‑2 treatments | — |
| 2 | Instil Bio R&D company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers | $371M | 68 mo ago | 23 | Bronson Crouch Chairman & CEO | 178 patents Engineered immune receptors for targeted costimulation in adoptive cell therapy | — |
| 3 | Kymab Provider of monoclonal antibody therapeutics for multiple diseases | $348M | 86 mo ago | 183 | Allan Bradley Founder & Director | 872 patents Therapeutic antibodies targeting immune checkpoints and T‑cell co‑stimulatory receptors for immuno‑oncology and autoimmunity. | — |
| 4 | Skyepharma Developer of small molecule based oral and inhalation products for the treatment of various diseases | $327M | 136 mo ago | 186 | — | — | — |
| 5 | 4D Pharma Developer of drugs from gut bacteria for multiple diseases | $206M | 66 mo ago | 106 | Duncan Peyton Co-Founder & CEO | 1,120 patents Probiotic bacterial formulations and cannabinoid-based antiepileptic therapies | — |
| 6 | Pepgen Provider of various therapeutics | $158M | 61 mo ago | 54 | Caroline Godfrey Co-Founder | — | — |
| 7 | NeRRe Therapeutics Developing clinical and pre-clinical neurokinin receptor antagonists | $74M | 62 mo ago | 14 | Emiliangelo Ratti Co-Founder | 153 patents NK‑1 receptor antagonist drugs for chronic cough and mechanically‑induced pulmonary fibrosis | — |
| 8 | Syntaxin Bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. | $62M | 190 mo ago | 28 | — | 223 patents Engineered proteases and fusion proteins for therapeutic peptide production and disease suppression. | 1 partnership · 1 award |
| 9 | Curve Therapeutics Developer of Microcycle-based therapeutics addressing intracellular targets for cancer and inflammation | $47M | 30 mo ago | 14 | Simon Kerry Chief Executive Officer | — | — |
| 10 | Infirst OTC products developed from existing drugs. | $38M | 161 mo ago | 8 | Manfred Scheske CEO | — | — |
| 11 | Magnus Life Science Therapeutics for wide range of diseases | $25M | 143 mo ago | 11 | — | — | — |
| 12 | Chronos Therapeutics Drug discovery, development, screening and re-positioning | $16M | 142 mo ago | 4 | — | 101 patents Small-molecule orexin receptor antagonists for sleep and neuropsychiatric therapies. | — |
| 13 | CytoSeek Developer of cell therapies for targeting solid tumours | $7M | 36 mo ago | 9 | — | 7 patents Targeted immunotherapy using modified globin and dextran crosslinkers for cancer | — |
| 14 | Futura Medical Develops drugs for pain relief and sexual health using transdermal technology | $6M | 64 mo ago | 12 | — | 147 patents Formulating and testing topical drug delivery systems for skin applications. | — |
| 15 | Oxfordpharmascience Drug development company that re-develops approved drugs using proprietary formulation technologies | $5M | 154 mo ago | 2 | — | — | — |
| 16 | TheraCryf Developer of therapeutics for oncology and behavioral brain disorders | $281K | 87 mo ago | 10 10 → 10 (+0%) | Huw Jones CEO | 2 patents Pharmaceutical crystalline forms for active drug compounds | — |
| 17 | GSK Manufacturer of pharmaceutical medicines and vaccines for human health conditions | — | 32 mo ago | 90,913 90,913 → 92,111 (+1%) | Dame Walmsley CEO | — | — |
Top 12 Diversified Pharmaceuticals companies in England
#1
Public · Cambridge, England · founded 1999 · 83100 employees$4.1Braised▾
Developer of pharmaceutical medicines for oncology and various chronic diseases. Research activities focus on the discovery and production of therapeutics targeting cancer, cardiovascular conditions, renal disorders, metabolic diseases, respiratory ailments, and immunological conditions. The business also develops treatments for rare diseases and infectious conditions. Operations involve clinical trials and the application of data science to identify new molecular entities for medical use.
- Jul 2025Grant (prize money)$6.1M
- Dec 2021Post IPO$6.1M
- May 2021Grant (prize money)$334.2K
- Jan 2021Grant (prize money)$371.8K
#2
Series A · Southampton, England · founded 2019 · 14 employees$46.7Mraised▾
Developer of Microcycle-based therapeutics addressing intracellular targets for cancer and inflammation. The company’s platform enables discovery of peptide macrocycles by functional screening inside mammalian cells. It focuses on creating macrocycle-derived drugs that address high priority disease targets. The properties of Microcycles unlocks targets that conventional methods have struggled to reach.
- Feb 2024Series A$43.9M
- Jun 2019Seed$2.9M
#3
Late Stage · Leeds, England · founded 2008 · 106 employees$205.7Mraised▾
Developer of drugs from gut bacteria for multiple diseases. The company leverages a MicroRx platform, for developing live biotherapeutic products for a large number of diseases including cancer, gastrointestinal disease, respiratory disease, and conditions of the central nervous system (CNS).
- Mar 2021Post IPO$24M
- Jul 2020Post IPO$9.7M
- Feb 2020Post IPO$28.7M
- 2016Post IPO$27M
#4
Public · Manchester, England · founded 2018 · 23 employees$370.6Mraised▾
R&D company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers
- Dec 2020Series D$185.4M
- Jun 2020Series C$170.2M
- Mar 2019Series B$15M
#5
Acquired · Cambridge, England · founded 2009 · 183 employees$348Mraised▾
Kymab develops monoclonal antibody therapeutics for oncology and other disorders. Its proprietary KyMouse platform allows for the precise production of a diverse range of fully-humanized monoclonal antibodies. It has three preclinical programs for oncology and several discovery stage programs for other indications.
- Jun 2019Series C$10M
- Mar 2019Series C$68.1M
- Jul 2017Series C$49.9M
- Jan 2017Grant (prize money)$9M
#6
Public · Oxford, England · founded 2018 · 54 employees$157.5Mraised▾
Pepgen provides various biopharmaceutical therapies. The company develops novel autoimmune, inflammatory, and viral therapies. The company also developed the next generation of short peptides that attach to antisense oligonucleotides to improve the delivery to muscles.
- Jul 2021Series B$112.5M
- Nov 2020Series A$45M
- Jan 2020Grant (prize money)$69.9K
#7
Series A · Bristol, England · founded 2017 · 9 employees$7.3Mraised▾
Developer of cell therapies for targeting solid tumors. The company is developing therapies for cancer, heart disease, osteoarthritis, and diabetic wound healing. They have developed artificial membrane-binding proteins that enable tissue-specific targeting and enhanced cell survivability.
- Sep 2023Series A$918.8K
- Mar 2021Series A$5M
- Nov 2019Grant (prize money)—
- May 2019Seed$1.4M
#8
Acquired · London, England · founded 1996 · 186 employees$326.5Mraised▾
SkyePharma is developing small molecule-based oral and inhalation products for the treatment of various diseases. It uses its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Its Geomatrix and Geoclock technologies enable controlled and timed-release versions of orally administered therapeutics Soctec, a novel gastric retention technology was specifically developed for molecules requiring absorption in the stomach or upper part of the intestine. Its inhalation technologies include formulation as well as device technologies and encompass Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs)
- May 2015Conventional Debt$38.7M
- Mar 2014Post IPO$219.3M
- Dec 2006Conventional Debt$68.5M
#9
Series B · Stevenage, England · founded 2012 · 14 employees$74.3Mraised▾
Developing clinical and pre-clinical neurokinin receptor antagonists
- Jul 2021Series B$27.7M
- Jan 2017Series B$28.2M
- Dec 2012Series A$18.4M
#10
Acquired · Abingdon, England · founded 2005 · 28 employees$62Mraised▾
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The company’s proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. Acquired by Ipsen in March 2013 and changed its name to Ipsen Bioinnovation in March 2015.
- Nov 2010Series C$29M
- Oct 2007Series B$33M
#11
Public · Guildford, England · founded 1997 · 12 employees$5.7Mraised▾
Futura Medical develops topically applied pharmaceutical drugs for pain relief and sexual health using its proprietary transdermal technology, DermaSys. Product pipeline includes: Sexual health (CSD500, MED2002) and Pain Relief (TPR100, TIB200, SPR300)
- May 2021Post IPO$14.1M
- Oct 2018Post IPO$7.3M
- Sep 2016Post IPO$14.6M
- Sep 2003Post IPO$2.8M
#12
Series A · London, England · founded 2012 · 8 employees$38Mraised▾
Infirst Healthcare is a company focused on improving existing drugs with IP rights and provide OTC products with improved effectiveness. The company's first product Dr. Cocoa is a cocoa-flavored cough liquid. It has five products: Dr. Cocoa, Flarin, Granulox, Unicough and BC1036. Flarin and Unicough are currently available in the UK, Dr. Cocoa is available in the US, Granulox is not commercially available and BC1036 is under European phase III clinical study. It has licensed its IP rights to Pernix Therapeutics Holdings in North America. It is also developing an ibuprofen-based product for the treatment of inflammatory pain.
- Mar 2013Series A$38M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.